Twenty-first Paterson symposium: bioactivation of quinone anti-tumor agents. by unknown
Br. J. Cancer (1987), 55, 327 330 © The Macmillan Press Ltd., 1987
MEETING REPORT
Twenty-first Paterson Symposium: bioactivation of quinone anti-tumour
agents
Held at the Paterson Institutefor Cancer Research, Christie Hospital & Holt Radium Institute, Manchester. 19-22 October 1986
Organisers: J. Butler, N.J.F. Dodd, E.J. Land & A.J. Swallow
There is tremendous scope for the imaginative development
of chemotherapy in the treatment of cancer. One approach,
which is currently of world-wide interest, starts with learning
about the metabolism of existing or potential anti-tumour
agents at a molecular level with a view to constructing new
molecules or developing improved methods of using the
agents. This is a particularly promising approach with
quinone anti-tumour agents, since they undergo metabolic
transformations which are significant for anti-cancer actions
and/or for those damaging side effects which provide a
limiting factor in treatment. The Paterson Symposium
brought together a number of leading workers in the field,
who reported on recent work by themselves and their
collaborators.
Providing a perspective of the current place of
anthracyclines in cancer treatment, D. Crowther (Christie
Hospital and Holt Radium Institute, Manchester), said that
daunomycin (daunorubicin) and, especially, adriamycin
(doxorubicin) have become of first rank clinical importance,
adriamycin being used in all cases of adult leukaemia and in
some cases of children's leukaemia. The use of otherwise
lethal doses in conjunction with bone marrow
transplantation has led to marked improvements in
treatment. Adriamycin is now also being used with success in
the combination chemotherapy of Hodgkins disease and
other diseases. One problem is the serious side effects of
myelosuppression, nausea and vomiting, alopecia, local
tissue necrosis and, ultimately, cardiotoxicity. Few of the
new analogues tried have so far achieved much
improvement, although some such as mitozantrone show
promise. Another problem requiring research is resistance to
the drug. There is still a real need for new, less toxic, drugs.
Recent studies carried out by Farmitalia, the main
pioneers of anthracyclines as antitumour agents, reported by
S. Penco (Farmitalia Carlo Erba, Milan), have resulted in the
development of two new synthetic anthracyclines currently
under extensive clinical evaluation; epirubicin (4'
epiadriamycin) and idarubicin (4-demethoxy daunomycin).
In his view, epirubicin, an analogue of adriamycin in which
the stereochemistry of the C4' carbon has been inverted, is
significantly better tolerated and less cardiotoxic than the
parent, probably due to the ability of the drug to be a
substrate for human P-D-glucuronidase. Idarubicin shows
strong antileukaemic activity, the metabolite
13(s)idarubicinol also exhibiting pronounced anti-tumour
activity. An extensive programme of synthesis of
daunomycin-adriamycin analogues differing in the
substitution patterns of the anthraquinonoid moiety was
described, together with the evaluation of their preferred
conformations by NMR and/or X-ray studies. The analogues
exhibited varying redox properties and reactivities of
bioreduced species, deglycosidation depending upon
chromophore substitution. All anthracyclines studied were
reduced by NADPH-cytochrome P-450 reductase, some
exhibiting complex enzyme kinetics. Dr. Penco considered
the main target of these antibiotics to be the cellular DNA
whose conformation and function are thought to be
impaired by drug intercalation.
Most studies of the mode of action of adriamycin on cells
do in fact focus attention on its interaction with DNA.
However an important locus of action also appears to be the
cell membrane and cytoskeleton. This aspect was described
by J.A. Hickman (Pharmaceutical Sciences Institute, Aston
University). The erythrocyte is an ideal model system in
which changes in shape, from discocyte to echinocyte can be
produced, by either ATP depletion or calcium loading.
Amphipathic agents, such as the phenothiazines, can convert
the ATP depleted cells to the discocyte, and ultimately the
stomatocyte form, by a mechanical or chaotropic effect, but
have no influence on the calcium induced effect. Adriamycin,
on the other hand, blocks calcium induced echinocytosis and
does not promote stomatocyte formation. The shape of
erythrocytes is thought to be controlled via the
phosphorylated status of inositol lipids. There appears to be
a good correlation between inhibition, by adriamycin, of
inositol lipid metabolism and maintainance of cell shape and
it was suggested that, in dividing cells, such a mechanism
would have a profound effect on their proliferation.
A review of anthracycline resistance was presented by M.
Sehested (Ferlev Hospital, University of Copenhagen).
Acquired resistance is associated with a wide range of
phenotypical differences, although no phenotype is
universally present. One phenotype found in most drug
resistant cell lines presents as a decrease in net accumulation
of the drug. This may be associated with a decrease in
passive influx, a decrease in the number of intracellular
binding sites or an increase in energy dependent drug efflux.
It was suggested that plasma membrane traffic and vesicular
transport may play an important role. Vesicular traffic from
the plasma membrane to endosomes and back to the plasma
membrane has been demonstrated in several cell types. This
cycling of membrane is more rapid in drug resistant cells
than in wild type cells, as can be shown by the rate of
internalisation of the membrane marker, ferritin. Moreover.
the numbers of vesicles and endosomes are increased in thc
resistant lines, drug binding in lysosomal cell fractions is also
increased and resistance can be modified or reversed by
lysosomatropic agents.
Activation of anthracyclines and mitomycin C, an
important nonanthracycline quinone antitumour agent, was
discussed by N.R. Bachur (University of Maryland Cancer
Center, Baltimore). DNA is a prime target for both types of
drug; they bind to DNA, inhibit DNA repair enzymes and
DNA or RNA polymerases and produce single strand
breaks. Moreover, while they can be activated by
microsomes, nuclei are more reactive. This leads to the
formation of ESR detectable free radicals. By means of
cyclic voltametry, it is possible to reduce the drugs by one-
or two-electron steps, the former giving semiquinone
radicals, that are stable in dimethyl formamide. However, on
addition of water, a range of products is rapidly formed,
which has been separated by HPLC. These products are
similar to those observed during enzymatic reduction and
differ from the products of two-electron reduction. It is
concluded that the drugs are reduced, by specific
flavoproteins, in several one-electron steps, although in the
presence of oxygen the primary radicals are scavenged and
the resultant oxygen radicals may be a cause of toxicity.
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Several papers dealt with various aspects relating to the
initial steps of bioactivation. The nature of the changes
consequent on the one-electron reduction of daunomycin
have been studied by T.H. Koch (Department of Chemistry
and Biochemistry, University of Colorado) in vitro using a
mild free radical reducing agent. After formation of the
hydroquinone there is rapid loss of daunosamine to give a
quinone methide which slowly tautomerises to 7-
deoxydaunomycinone. The possibility of forcing the
formation of the pharmacologically inactive aglycone has
suggested the use of a water soluble variant of the reducing
agent as a useful antidote for anthracyclines. From
experiments with mice it could be useful in high-dose
therapy. It also strikingly alleviates the severity of skin
ulceration in animals. High skin toxicity is found when the
nucleophilic reactivity of the quinone methide state is high.
But does the ability of the drug to undergo redox cycling
also parallel skin toxicity? The highest skin toxicity among
the compounds studied was found with 5-iminodaunomycin.
This is harder to reduce than daunomycin. After the
formation of the 7-deoxyaglycone further reduction can give
rise to a naphthacenedione. Oxygen prevents this process
and permits radical cycling. Under hypoxia radical recycling
is prevented.
Some of the damage to DNA caused by antitumour
quinones has been attributed to the production of reactive
oxygen radical species from the reactions of the
semiquinones. J.M.C. Gutteridge (National Institute for
Biological Standards and Control, London) explained the
various ways in which hydroxyl radicals can be formed in
reactions involving quinones, oxygen, iron and a reducing
enzyme system. Low molecular weight complexes of iron
have been detected in both intra- and intercellular fluids and
these have been shown to be capable of initiating Fenton
reactions. In the presence of quinones the Fe"' complexes
produced from the Fenton reaction can be reduced back to
Fe" by the semiquinone radicals and hence the production
of hydroxyl radicals continues. However, one of the main
conclusions from this talk was that this kind of mechanism
is unlikely to occur for the antitumour quinones when
strongly intercalated with DNA. Several studies have shown
that once the quinone is intercalated it cannot be reduced to
the semiquinone radical by the reducing enzyme systems.
Adriamycin binds Fe"' with great affinity and this complex
may be one active form of the drug in vivo. The iron
mediated cycle of oxygen reduction and free radical
generation by adriamycin was described by J.L. Zweier
(National Heart, Lung and Blood Institute, Bethesda). Using
the techniques of optical, ESR and Mossbauer spectroscopy,
he showed that, while a high spin Fe"' complex of
adriamycin is rapidly formed, it slowly converts, under
anoxic conditions, to high spin Fe", with formation of an
oxidized adriamycin free radical. A transient iron-adriamycin
radical complex is also observed. The Fe" complex can be
converted to the ferric form on exposure to oxygen, with
concomitant formation of superoxide anion radicals, which
give rise to hydrogen peroxide. In the presence of excess
adriamycin, the cycle of oxygen reduction will continue. The
oxygen and adriamycin radicals so formed may mediate the
therapeutic and toxic effects of the drug. Using 13C-NMR,
the extent of paramagnetic broadening showed that the site
of iron binding to adriamycin was in the region of quinone
and hydroquinone groups on C,, and CI2, but not those on
C5 and C6. The initial site of radical formation in the Fe"'l-
adriamycin complex is the side chain of adriamycin.
Consequently, in the Fe''-daunomycin complex, daunomycin
is unable to reduce iron, no free radical from the drug is
detected and no oxygen consumption from °2-- formation is
observed.
Mitozantrone is structurally related to the anthracyclines
in that it has an anthracycline chromophore and analogous
cationic functional groups. In comparing mitozantrone with
adriamycin, L.H. Patterson (Department of Pharmaceutical
Chemistry, Leicester Polytechnic) demonstrated that
adriamycin gives an ESR signal in rat hepatocytes in which
glutathione synthesis is inhibited. This ESR signal was
attributed to the adriamycin semiquinone. However,
mitozantrone at the same concentrations does not give an
ESR signal. Neither drug induced lipid peroxidation but
interestingly, mitozantrone is significantly more toxic than
adriamycin. It was also suggested that the toxic effects of
adriamycin on heart tissues could be brought about by
reactions of the drug with oxymyoglobin. It is generally
believed that adriamycin semiquinone and superoxide
radicals are produced in vivo by one-electron reducing
enzymes. It was shown, however, that adriamycin reacts
directly with oxymyoglobin resulting in the production of
superoxide radicals and metmyoglobin. The metmyoglobin
undergoes reactions with hydrogen peroxide to produce a
peroxidase system. The eventual product from adriamycin in
these reactions was shown to be an extremely insoluble
precipitate which was not the normal adriamycin aglycone.
Although ESR is a powerful technique for identification of
free radicals, the signals obtained on enzymatic reduction of
anthracyclines consist of single lines, which do not allow
identification, although, from their g-value, they are assigned
to semiquinone radicals. R.P. Mason (National Institute of
Environmental Health Sciences, Research Triangle Park)
showed that, by addition of the non-aqueous solvents
ethanol or dimethyl sulphoxide, it was possible to obtain
spectra that were highly resolved. With the aid of computer
simulations and of selective deuteration of exchangable
protons, it has been possible to obtain positive identifi-
cations of the radicals. The radical obtained on enzymic
reduction of daunomycin changes with time, becoming more
immobilized and the ESR spectrum changing from isotropic
to axially symmetric. By addition of non-aqueous solvent, it
can be shown that the daunomycin semiquinone changes,
with time, to the 7-deoxydaunomycinone semiquinone and it
is suggested that this may form aggregates, that are
immobilized, on the ESR time scale. Dr. Mason also
presented recent results showing the reduction of various
naphthoquinones, by glutathione, to the corresponding
semiquinones, with concomitant conjugation to glutathione.
a-Naphthol inhibits protein and DNA synthesis and the
growth of colonic tumour cells. In vitro it is oxidised by
mixed function oxidases to 1,2- and 1,4-naphthoquinones
and has been shown to be selectively toxic in vitro towards
certain tumour cells compared to the normal cell lines. G.M.
Cohen (School of Pharmacy, University of London) discussed
the many mechanisms of activation and selectivity of a-
naphthol and explained that naphthol can form sulphonated
ester conjugates or glucuronide adducts. In certain tumours
the major product is the glucuronic acid conjugate and this
is one difference between the tumour cell compared to the
normal cell. ax-Naphthol also leads to a depletion in
intracellular glutathione and dicoumarol increases this
depletion and the toxicity. This implies that the one-electron
reduction processes are more damaging than the two-
electron processes. Purified 1,2- and 1,4-naphthoquinones are
also toxic and are similarly affected by dicoumarol. a-
Naphthol has also been shown to be a substrate for
peroxidase and inhibits ribonucleotide reductase, possibly by
scavenging the tyrosine radical at the active site.
Continuing the theme of naphthoquinones, S. Orrenius
(Karolinska Institute, Stockholm) discussed the mechanisms
ofmenadione (2-methyl-1,4-naphthoquinone)-induced damage
in various intact cell systems and in particular, the rat
hepatocyte. The marker for toxicity is the formation of
characteristic blebs on the cell surface which is an early
morphological sign of cell injury. The extent of blebbing can
be modified by dicoumarol or by glutathione inhibitors. The
quinone can be reduced in hepatocytes by one- or two-
electron processes, the latter is inhibited by dicoumarol, or
can add directly to GSH and -SH groups in proteins. Both
the reduction and addition processes lead to a net GSH andBIOACTIVATION OF QUINONE ANTI-TUMOUR AGENTS 329
protein -SH depletion. During these processes there is a
mobilisation and loss of calcium from the mitochondrial and
extramitochondrial compartments and an increase in
cytosolic calcium. Among its many effects, calcium
influences actin binding capacity which may be partly
responsible for the onset of blebbing. The discussion at the
end of this talk was extensive and it was generally accepted
that this type of mechanism could also occur for some
antitumour drugs.
J.R. Brown (Department of Pharmaceutical Chemistry,
Sunderland Polytechnic) posed a number of questions
regarding the initial steps of bioactivation of anthraquinones,
the first of which was whether the oxidation of the
hydroquinone ring of adriamycin and daunomycin could be
significant as well as the more widely studied reduction.
With respect to the latter, could two-electron reduction be
used to avoid oxygen-linked problems associated with the
formation of the semiquinone? He wondered what
information about the reduction could be obtained from the
biological data. Were DNA binding or redox cycling of
greater significance? Computer graphics and kinetic studies
had been made of the binding to DNA of a number of
substituted anthraquinones. This property depends markedly
on substitution. All of the compounds could be reduced by
mouse liver microsomes. They varied in the effectiveness
with which they could generate 02- This was not due to
differences in one-electron reduction potential but because of
differing abilities to act as substrate for the enzyme.
The chemistry of semiquinones whether formed via one-
electron oxidation or one-electron reduction, and other
intermediates, can be investigated in an effective way by
pulse radiolysis. A.J. Swallow (Paterson Institute for Cancer
Research, Manchester) showed how the species can be
formed in aqueous solutions, and how optical absorption
spectra, values of pKa, thermodynamic reduction potential
and reaction rate constants can be obtained. Naphthazarin, a
model compound for adriamycin, has a reduced semiquinone
which is extraordinarily stable. The reduced semiquinones of
adriamycin and daunomycin are even more stable with
respect to dismutation, but decay by intramolecular
processes within about a second. The semiquinone of
mitomycin C readily dismutes. The hydroquinone form
undergocs two pH-dependent principal reactions over
seconds. Reduction products as identified by HPLC are the
same whether reduction is effected pulse radiolytically or
enzymically.
AZQ(diaziquone,2,5-diaziridinyl-3,6-bis(carbethoxyamino)-
1,4-benzoquinone) is currently undergoing clinical trials.
J. Butler (Paterson Institutefor Cancer Research, Manchester)
reported on the consequences of one-electron reduction of
this and a number of related compounds as studied by pulse
radiolysis and HPLC. AZQ crosslinks DNA, induces strand
breaks and produces free radicals when reduced by a
number of mild reductants. Its semiquinone dismutes
hundreds of times more slowly than some other semi-
quinones. The resulting hydroquinone undergoes aziridine
ring opening over a period of minutes. The rate of the
reaction depends on pH. In the presence of oxygen the
hydroquinones thus formed react to give ring opened
quinones. He suggested that the reaction of the hydro-
quinone with oxygen is not a two-electron process but
rather produces, in the first instance, a semiquinone radical
and 02 - The semiquinone then reacts with oxygen to give
more 02-- The superoxide radicals can dismute to form
H202. Such one-electron steps could be common if not
universal intermediate stages in oxidation by oxygen.
Mitomycin C and porphyromycin are more toxic towards
hypoxic cells than fully oxygenated cells. S.R. Keyes
(Comprehensive Cancer Center, Yale University) discussed the
various mechanisms of toxicity and reported on a
preliminary clinical trial on the use of these drugs and
dicoumarol in combination with radiotherapy. Dicoumarol
significantly increased the toxicity of mitomycin C and
radiation towards tumour cells but it is not in itself a
radiosensitiser nor toxic. In hypoxia the NADPH-
cytochrome c reductase activity is at least partly responsible
for the activation of mitomycin C to toxic products.
Dicoumarol, a supposedly specific inhibitor of the DT
diaphorase system, results in an increase in the formation of
reactive electrophiles for mitomycin C under hypoxic
conditions implying that it is inhibiting an enzyme that
would normally metabolize the drug to non-active products.
Dicoumarol also eliminates the DNA cross links produced
by mitomycin C suggesting that this type of cross link is not
solely responsible for the toxicity of the drug. Evidence was
presented that suggests protein-DNA cross links may be
more important to the toxicity in hypoxic conditions.
Probably one of the most controversial points of this
presentation was that dicoumarol is not necessarily an
inhibitor of the DT diaphorase system. L1210 cells have high
NADPH-cytochrome c reductase activity but no measurable
DT diaphorase activity. However, the increase in toxicity
produced by dicoumarol is still present in hypoxic L1210
cells. This suggests that dicoumarol inhibits at least one
other enzyme besides the diaphorase system.
M. Tomasz (Hunter College, City University of New York)
described the first reported isolation and structure
determination of the major covalent adducts formed on
reaction of DNA with chemically or enzymatically activated
mitomycin C. Activation of mitomycin C in the presence of
calf thymus DNA using NADPH-cytochrome c reductase,
xanthine oxidase or H2/PtO2 was found to result in covalent
complex formation. Digestion of the complex followed by
HPLC yielded N2-(2"JJ,7"diaminomitosen- I"ox-yl)2'deoxy-
gaunosine(I)as themajor DNA alkylation product togetherwith
two minor monoadducts identified as the 1"f stereoisomer of
I and 10'-decarbamoyl-I, proof of these structures being
gained by IH NMR, MS, FTIR and CD. The same results
were obtained with poly (dG-dC).poly(dG-dC), although in
this case an additional minor adduct peak was found due to
a crosslinking adduct. The latter resulted from the addition
of one mitomycin to two guanosines, the second guanosine
being attached at the 10' position. This biadduct was also
isolated from rats injected with mitomycin C. Space-filling
molecular model building indicates a snug fit of the guanine
N2-linked drug monoadduct inside the minor groove of
B-DNA with no appreciable distortion of the DNA structure,
and also that the biadduct is even less disturbing to DNA
than the monoadduct.
Beginning the final morning, J.M. Bruce (Department of
Chemistry, University of Manchester) presented an overview
of quinone activity informed by his own knowledge as an
organic chemist, commenting upon mechanistic aspects of
some of the earlier presentations. Quinones, anti-aromatic
diketone systems which, when reduced by single electrons,
give the corresponding aromatic semiquinone radicals, have
inherent reactivity and on bioactivation can lead to new
species of differing reactivities. Under hypoxic conditions,
e.g. in solid tumours, quinones can be reduced to
semiquinones. The ability of quinones to accept electrons is
reflected in their half-wave reduction potentials which can be
raised by substituents which stabilise the semiquinone, e.g.
CN and CI, and lowered by others which destabilise Q-,
e.g. CH3 and CH30. If some oxygen is present,
semiquinones may react to give superoxide which can
ultimately lead to oxygen toxicity via H202 and OH.
Quinones can also decay to give other active species such as
quinone methides which are likewise reactive towards
nucleophiles. As a supporter of quinone methide intervention
in anticancer drug activity, Dr. Bruce suggested that at least
one of the covalent bonds resulting in the adducts described
by Dr Tomasz result from an interaction of a quinone
methide derived from mitomycin C.
The subject of polarographic half-wave potentials was
further developed by J.M. Moiroux (Ecole Normale
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described a spectroelectrochemical study of the 1- and 2-
electron reduction of a group of substituted anthraquinones
in aprotic medium (DMF), the ultimate aim being to see if
there is any correlation between anthracycline reducibility
and cytotoxicity and/or cardiotoxicity. Only the anthra-
quinone derivatives without hydroxy substituents had
reduction potentials more negative than the 02/02-- couple,
yet for the hydroxyanthraquinones the radical anions were
still oxidised by oxygen, the electron transfer being
accompanied by a proton transfer between the OH group
and 02-,yielding HO2 and the conjugate base of the
original anthraquinone. In DMF the semiquinone of
daunomycin was found to be stable, glycoside elimination
and formation of the basic form of the quinone methide only
occurring after addition of the second electron. Kinetic
studies by reverse pulse polarography showed that the
glycoside elimination rate varied on introducing protons into
the medium and also with the structure of the sugar moiety.
The conference concluded with a description by H. Berg
(Zentralinstitiitfur Mikrobiologie undExperimentelle Therapie,
Jena) of a broad, mainly physicochemical, study of a series
of eight anthracyclines: aclacinomycin A, adriamycin,
daunomycin, f,-rhodomycin-II, /3-rhodomycin-I, carmino-
mycin, iremycin and 5-imino daunomycin. The anthracycline
properties investigated included dimerisation, equilibrium
and kinetic constants for their complexes with DNA,
nucleoproteins and oligonucleotides, redox reactions,
deglycosidation and peroxide formation. A close correlation
was found between the anthracycline-DNA binding constant
and drug antimicrobial activity against Bacillus subtilis
ATCC 6633. The kinetics of daunomycin-DNA association
followed by the temperature jump technique fitted two
exponentials. Aclacinomycin was found to have the highest
affinity for DNA, the largest binding area (4 base pairs), to
be a more efficient inhibitor of DNA and RNA synthesis
than adriamycin or daunomycin, and to have the most
positive reduction potential, recorded electrochemically.
correlating with low cardiotoxicity. A general conclusion
from all these studies, consistent with the results presented in
several other contributions at this symposium, was that the
cytotoxic effects of anthracyclines are likely to operate via
several different molecular mechanisms.
In conclusion, the contents of the symposium, chosen to
be on a limited topic, amply demonstrate the wide range of
approaches currently being enthusiastically applied to studies
of the bioactivation of quinone anti-tumour agents. The high
quality of the talks, and the lively discussions which followed
each, encourage the feeling that, during the next few years,
the fundamentals of this aspect of cancer chemotherapy
should become established, leading to the production of
valuable new drugs.
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